Marina Noris

List of Publications by Year in Descending Order

208 papers	15,826 citations	66 h-index	122 g-index
222 ext. papers	18,023 ext. citations	8.7 avg, IF	6.54 L-index

#	Paper	IF	Citations
208	The state of complement in COVID-19.. *Nature Reviews Immunology*, **2021**,	36.5	20
207	C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. *Blood Advances*, **2021**,	7.8	7
206	Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice. *Stem Cell Research and Therapy*, **2021**, 12, 332	8.3	0
205	Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis. *Frontiers in Immunology*, **2021**, 12, 711915	8.4	0
204	and Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. *Frontiers in Genetics*, **2021**, 12, 670727	4.5	1
203	Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice. *Nephrology Dialysis Transplantation*, **2021**,	4.3	5
202	The case of complement inhibitors. *Advances in Biological Regulation*, **2021**, 81, 100822	6.2	1
201	Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. *Nephrology Dialysis Transplantation*, **2021**,	4.3	3
200	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study.. *PLoS ONE*, **2021**, 16, e0261113	3.7	4
199	Molecular Studies and an Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant. *Frontiers in Medicine*, **2020**, 7, 579418	4.9	3
198	Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11cF4/80 Macrophages through IL-1R8 Regulation. *Journal of the American Society of Nephrology: JASN*, **2020**, 31, 517-531	12.7	5
197	The case of complement activation in COVID-19 multiorgan impact. *Kidney International*, **2020**, 98, 314-322	9.9	182
196	Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule?. *Kidney International*, **2020**, 98, 1084-1087	9.9	5
195	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. *Blood*, **2020**, 136, 2103-2117	2.2	23
194	Autotaxin Inhibitor Protects from Chronic Allograft Injury in Rat Kidney Allotransplantation. *Nephron*, **2020**, 144, 38-48	3.3	4
193	Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. *Frontiers in Genetics*, **2019**, 10, 681	4.5	7
192	C3 glomerulopathy - understanding a rare complement-driven renal disease. *Nature Reviews Nephrology*, **2019**, 15, 129-143	14.9	109

191	Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. *Frontiers in Immunology*, **2019**, 10, 853	8.4	15
190	An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. *American Journal of Kidney Diseases*, **2019**, 74, 56-72	7.4	36
189	Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association. *Nephron*, **2019**, 142, 264-270	3.3	1
188	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. *American Journal of Kidney Diseases*, **2019**, 74, 224-238	7.4	22
187	Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. *Pediatric Nephrology*, **2019**, 34, 1311-1323	3.2	20
186	Hemolytic Uremic Syndrome **2019**, 294-301.e2		
185	Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?. *Kidney International*, **2019**, 96, 13-15	9.9	5
184	More about Factor H Autoantibodies in Membranous Nephropathy. *New England Journal of Medicine*, **2019**, 381, 1590-1592	59.2	5
183	Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. *Transplantation*, **2019**, 103, 1121-1130	1.8	9
182	Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. *Journal of Immunology*, **2018**, 200, 2464-2478	5.3	89
181	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. *Diabetes*, **2018**, 67, 1414-1427	0.9	71
180	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. *Journal of the American Society of Nephrology: JASN* , **2018**, 29, 283-294	12.7	48
179	Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome. *Journal of the American Society of Nephrology: JASN*, **2018**, 29, 240-249	12.7	19
178	ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A "KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES" (KDIGO) CONTROVERSIES CONFERENCE. *Nephrology (Saint-Petersburg)*, **2018**, 22, 18-39	0.4	
177	Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. *Frontiers in Immunology*, **2018**, 9, 2329	8.4	15
176	Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell Response. *American Journal of Transplantation*, **2017**, 17, 2312-2325	8.7	22
175	Hemolytic Uremic Syndrome in Pregnancy and Postpartum. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 1237-1247	6.9	104
174	Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. *Nature Communications*, **2017**, 8, 983	17.4	85

173	Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement. *Seminars in Nephrology*, **2017**, 37, 447-463	4.8	13
172	Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival. *Scientific Reports*, **2017**, 7, 11518	4.9	49
171	Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. *Journal of Immunology*, **2017**, 199, 1021-1040	5.3	37
170	Association of CFHR1 homozygous deletion with acute myelogenous leukemia in the European population. *Leukemia and Lymphoma*, **2016**, 57, 1234-7	1.9	2
169	Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 2356-2367	15.4	8
168	Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 1305-11	12.7	24
167	Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. *Journal of Biological Chemistry*, **2016**, 291, 8214-30	5.4	11
166	Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. *Molecular Immunology*, **2016**, 71, 131-142	4.3	84
165	Liver transplantation for aHUS: still needed in the eculizumab era?. *Pediatric Nephrology*, **2016**, 31, 759-68	3.2	18
164	Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 340-5	15.4	2
163	Podocyte dysfunction in atypical haemolytic uraemic syndrome. *Nature Reviews Nephrology*, **2015**, 11, 245-52	14.9	38
162	Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study. *Annals of Oncology*, **2015**, 26, 1363-71	10.3	28
161	The role of complement in C3 glomerulopathy. *Molecular Immunology*, **2015**, 67, 21-30	4.3	65
160	Atypical aHUS: State of the art. *Molecular Immunology*, **2015**, 67, 31-42	4.3	177
159	Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. *American Journal of Kidney Diseases*, **2015**, 66, 1067-70	7.4	21
158	ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. *Clinical Journal of the American Society of Nephrology: CJASN*, **2015**, 10, 2002-12	6.9	9
157	A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 209-19	12.7	69
156	Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. *Pediatric Nephrology*, **2015**, 30, 167-72	3.2	54

155	Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. *Blood*, **2015**, 125, 2359-69	2.2	79
154	Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015. *American Journal of Kidney Diseases*, **2015**, 66, 359-75	7.4	103
153	Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. *Clinical Journal of the American Society of Nephrology: CJASN*, **2015**, 10, 1011-9	6.9	39
152	Hemolytic uremic syndrome. *Seminars in Immunopathology*, **2014**, 36, 399-420	12	96
151	Cardiovascular complications in atypical haemolytic uraemic syndrome. *Nature Reviews Nephrology*, **2014**, 10, 174-80	14.9	46
150	Kidney transplantation from a donor with acute kidney injury: an unexpected outcome. *American Journal of Transplantation*, **2014**, 14, 977-8	8.7	0
149	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. *Blood*, **2014**, 124, 1715-26	2.2	220
148	A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models. *Journal of Immunology*, **2014**, 193, 5567-75	5.3	12
147	An unanticipated role for survivin in organ transplant damage. *American Journal of Transplantation*, **2014**, 14, 1046-60	8.7	9
146	Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?. *Journal of the American Society of Nephrology: JASN*, **2014**, 25, 2053-65	12.7	74
145	Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity. *Age*, **2013**, 35, 993-1005		38
144	Overview of complement activation and regulation. *Seminars in Nephrology*, **2013**, 33, 479-92	4.8	415
143	Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. *Transplant International*, **2013**, 26, 867-78	3	129
142	Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. *American Journal of Transplantation*, **2013**, 13, 2201-6	8.7	42
141	Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. *Journal of the American Society of Nephrology: JASN*, **2013**, 24, 475-86	12.7	254
140	ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy. *Diabetes*, **2013**, 62, 3599-609	0.9	23
139	Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. *Current Opinion in Nephrology and Hypertension*, **2013**, 22, 704-12	3.5	47
138	Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. *Nephrology Dialysis Transplantation*, **2013**, 28, 2246-59	4.3	47

137	In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. *Journal of Immunology*, **2013**, 191, 2818-28	5.3	56
136	Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. *American Journal of Transplantation*, **2012**, 12, 2373-83	8.7	126
135	Prolonged cold ischemia accelerates cellular and humoral chronic rejection in a rat model of kidney allotransplantation. *Transplant International*, **2012**, 25, 347-56	3	14
134	Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. *Blood*, **2012**, 120, 440-8	2.2	91
133	Thrombotic microangiopathies **2012**, 278-282		1
132	STEC-HUS, atypical HUS and TTP are all diseases of complement activation. *Nature Reviews Nephrology*, **2012**, 8, 622-33	14.9	275
131	Discordant phenotype in monozygotic twins with renal coloboma syndrome and a PAX2 mutation. *Pediatric Nephrology*, **2012**, 27, 1989-93	3.2	12
130	Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. *Kidney International*, **2012**, 81, 903-18	9.9	28
129	Eculizumab in a patient with dense-deposit disease. *New England Journal of Medicine*, **2012**, 366, 1161-3	59.2	119
128	Non-muscle myosins and the podocyte. *CKJ: Clinical Kidney Journal*, **2012**, 5, 94-101	4.5	11
127	Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice. *Journal of Immunology*, **2012**, 189, 3661-8	5.3	29
126	Posttransplant recurrence of atypical hemolytic uremic syndrome. *Journal of Nephrology*, **2012**, 25, 911-7	4.8	4
125	Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 412-22	6.9	231
124	Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats. *Transplantation*, **2011**, 92, 271-9	1.8	21
123	Rabbit anti-rat thymocyte immunoglobulin preserves renal function during ischemia/reperfusion injury in rat kidney transplantation. *Transplant International*, **2011**, 24, 829-38	3	14
122	Erythropoietin enhances immunostimulatory properties of immature dendritic cells. *Clinical and Experimental Immunology*, **2011**, 165, 202-10	6.2	25
121	Thrombotic microangiopathies: from animal models to human disease and cure. *Contributions To Nephrology*, **2011**, 169, 337-350	1.6	10
120	MYO1E mutations and childhood familial focal segmental glomerulosclerosis. *New England Journal of Medicine*, **2011**, 365, 295-306	59.2	195

119	Embryonic stem cells, derived either after in vitro fertilization or nuclear transfer, prolong survival of semiallogeneic heart transplants. *Journal of Immunology*, **2011**, 186, 4164-74	5.3	8
118	Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. *Journal of Immunology*, **2011**, 187, 172-80	5.3	186
117	Residual Plasmatic Activity of ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Correlates with Disease Phenotype. *Blood*, **2011**, 118, 2219-2219	2.2	
116	Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. *Seminars in Thrombosis and Hemostasis*, **2010**, 36, 641-52	5.3	37
115	Toward a B-cell signature of tolerance?. *Kidney International*, **2010**, 78, 435-7	9.9	5
114	Klotho in acute kidney injury: biomarker, therapy, or a bit of both?. *Kidney International*, **2010**, 78, 1208-10	9.9	12
113	Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. *Seminars in Nephrology*, **2010**, 30, 395-408	4.8	23
112	Immunomodulatory effects of mesenchymal stromal cells in solid organ transplantation. *Current Opinion in Organ Transplantation*, **2010**, 15, 731-7	2.5	21
111	Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. *Clinical Journal of the American Society of Nephrology: CJASN*, **2010**, 5, 1844-59	6.9	661
110	Thrombotic microangiopathy after kidney transplantation. *American Journal of Transplantation*, **2010**, 10, 1517-23	8.7	161
109	Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura **2010**, 349-364		
108	The Toll-IL-1R member Tir8/SIGIRR negatively regulates adaptive immunity against kidney grafts. *Journal of Immunology*, **2009**, 183, 4249-60	5.3	44
107	Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 940-9	12.7	139
106	Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells. *Kidney International*, **2009**, 75, 1050-9	9.9	24
105	Thrombomodulin mutations in atypical hemolytic-uremic syndrome. *New England Journal of Medicine*, **2009**, 361, 345-57	59.2	418
104	Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 123-30	12.7	74
103	Atypical hemolytic-uremic syndrome. *New England Journal of Medicine*, **2009**, 361, 1676-87	59.2	934
102	Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. *Transplantation*, **2009**, 88, 614-9	1.8	58

101	Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. *Clinical and Experimental Immunology*, **2008**, 151, 199-209	6.2	21
100	Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. *Molecular Immunology*, **2008**, 45, 95-105	4.3	113
99	Polymorphisms of EDNRB, ATG, and ACE genes in salt-sensitive hypertension. *Canadian Journal of Physiology and Pharmacology*, **2008**, 86, 505-10	2.4	37
98	Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 1158-67	12.7	54
97	The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 639-46	12.7	73
96	Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. *Journal of Immunology*, **2008**, 181, 3933-46	5.3	370
95	Mutations in FN1 cause glomerulopathy with fibronectin deposits. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 2538-43	11.5	96
94	Propionyl-L-carnitine prevents early graft dysfunction in allogeneic rat kidney transplantation. *Kidney International*, **2008**, 74, 1420-8	9.9	6
93	Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. *Blood*, **2008**, 111, 624-32	2.2	116
92	Effect of seliciclib (CYC202, R-roscovitine) on lymphocyte alloreactivity and acute kidney allograft rejection in rat. *Transplantation*, **2008**, 85, 1476-82	1.8	5
91	Complement and the atypical hemolytic uremic syndrome in children. *Pediatric Nephrology*, **2008**, 23, 1957-72	3.2	161
90	The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. *Human Mutation*, **2007**, 28, 222-34	4.7	142
89	Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. *Clinical Journal of the American Society of Nephrology: CJASN*, **2007**, 2, 591-6	6.9	51
88	Role of thymic- and graft-dependent mechanisms in tolerance induction to rat kidney transplant by donor PBMC infusion. *Kidney International*, **2007**, 71, 1132-41	9.9	3
87	Regulatory T cells and T cell depletion: role of immunosuppressive drugs. *Journal of the American Society of Nephrology: JASN*, **2007**, 18, 1007-18	12.7	202
86	Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells. *Journal of the American Society of Nephrology: JASN*, **2007**, 18, 506-14	12.7	49
85	Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. *Transplantation*, **2007**, 84, 956-64	1.8	84
84	DnIKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4+CD25- cells with tolerogenic properties. *Transplantation*, **2007**, 83, 474-84	1.8	19

83	Chapter 14 Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. *Handbook of Systemic Autoimmune Diseases*, **2007**, 257-282	0.3	
82	Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. *Molecular Immunology*, **2007**, 44, 111-22	4.3	105
81	Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. *Molecular Immunology*, **2007**, 44, 1704-8	4.3	35
80	Where next with atypical hemolytic uremic syndrome?. *Molecular Immunology*, **2007**, 44, 3889-900	4.3	47
79	Induction of Tolerance in Allotransplantation **2007**, 461-474		
78	Thrombotic thrombocytopenic purpura--then and now. *Seminars in Thrombosis and Hemostasis*, **2006**, 32, 81-9	5.3	43
77	Complement factor h gene abnormalities in haemolytic uraemic syndrome: from point mutations to hybrid gene. *PLoS Medicine*, **2006**, 3, e432	11.6	6
76	Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, 1665-72	12.7	29
75	Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H). *Clinical Journal of the American Society of Nephrology: CJASN*, **2006**, 1, 539-45	6.9	25
74	Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. *Clinical Journal of the American Society of Nephrology: CJASN*, **2006**, 1, 88-99	6.9	172
73	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. *Thrombosis and Haemostasis*, **2006**, 96, 454-464	7	64
72	Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. *Blood*, **2006**, 108, 1267-79	2.2	561
71	Non-Shiga toxin-associated hemolytic uremic syndrome **2006**, 65-83		2
70	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. *Thrombosis and Haemostasis*, **2006**, 96, 454-64	7	16
69	Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. *Thrombosis and Haemostasis*, **2005**, 93, 443-52	7	75
68	Reduced nitric oxide bioavailability in a baboon model of Shiga toxin mediated hemolytic uremic syndrome (HUS). *Renal Failure*, **2005**, 27, 635-41	2.9	7
67	Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. *American Journal of Pathology*, **2005**, 167, 1173-81	5.8	100
66	Hemolytic uremic syndrome. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 1035-50	12.7	390

65	Mechanisms of disease: Pre-eclampsia. *Nature Clinical Practice Nephrology*, **2005**, 1, 98-114; quiz 120		217
64	Natural versus adaptive regulatory T cells. *Contributions To Nephrology*, **2005**, 146, 121-131	1.6	20
63	Dendritic cells genetically engineered with adenoviral vector encoding dnIKK2 induce the formation of potent CD4+ T-regulatory cells. *Transplantation*, **2005**, 79, 1056-61	1.8	28
62	Effect of a novel immunosuppressant, ST1959, on the immune system and renal allograft survival in rats. *Transplantation*, **2005**, 80, 231-6	1.8	2
61	Pretransplant donor peripheral blood mononuclear cells infusion induces transplantation tolerance by generating regulatory T cells. *Transplantation*, **2005**, 79, 1034-9	1.8	26
60	Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. *Blood*, **2005**, 106, 925-8	2.2	52
59	Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. *Kidney International*, **2005**, 67, 1753-61	9.9	107
58	Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. *American Journal of Transplantation*, **2005**, 5, 1146-50	8.7	109
57	Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?. *Nature Clinical Practice Nephrology*, **2005**, 1, 2-3		16
56	Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 1177-83	12.7	116
55	Nitric oxide synthetic capacity in relation to dialysate temperature. *Blood Purification*, **2004**, 22, 203-9	3.1	17
54	Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. *Kidney International*, **2004**, 66, 1959-65	9.9	43
53	L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. *Hypertension*, **2004**, 43, 614-22	8.5	124
52	Donor hematopoietic cells: central versus peripheral tolerance. *Current Opinion in Organ Transplantation*, **2004**, 9, 284-288	2.5	
51	Diverse Functional Implications of ADAMTS13 Gene Mutations in Patients with TTP and Congenital Deficiency.. *Blood*, **2004**, 104, 513-513	2.2	2
50	ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. *Kidney International*, **2003**, 64, 2253-61	9.9	25
49	Familial haemolytic uraemic syndrome and an MCP mutation. *Lancet, The*, **2003**, 362, 1542-7	40	268
48	Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. *Human Molecular Genetics*, **2003**, 12, 3385-95	5.6	260

47	Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. *Journal of Clinical Investigation*, **2003**, 111, 1181-90	15.9	267
46	Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. *American Journal of Kidney Diseases*, **2002**, 40, 783-93	7.4	57
45	Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. *Kidney International*, **2002**, 61, 1064-78	9.9	54
44	ACE inhibitors and AT1 receptor antagonists: is two better than one?. *Kidney International*, **2002**, 61, 1545-7	9.9	9
43	Single Strand Conformation Polymorphism (SSCP) as a quick and reliable method to genotype M235T polymorphism of angiotensinogen gene. *Clinical Biochemistry*, **2002**, 35, 363-8	3.5	12
42	von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. *Blood*, **2002**, 100, 778-85	2.2	183
41	Factor H family proteins: on complement, microbes and human diseases. *Biochemical Society Transactions*, **2002**, 30, 971-8	5.1	216
40	Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. *Lancet, The*, **2002**, 359, 1671-2	40	139
39	Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. *Kidney International*, **2001**, 60, 653-63	9.9	45
38	Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. *Kidney International*, **2001**, 60, 831-46	9.9	325
37	Complement factor H and hemolytic uremic syndrome. *International Immunopharmacology*, **2001**, 1, 461-88	3	22
36	Thymic microchimerism correlates with the outcome of tolerance-inducing protocols for solid organ transplantation. *Journal of the American Society of Nephrology: JASN*, **2001**, 12, 2815-2826	12.7	23
35	The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. *Journal of the American Society of Nephrology: JASN* , **2001**, 12, 297-307	12.7	219
34	Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. *Journal of the American Society of Nephrology: JASN*, **2001**, 12, 1937-1946	12.7	29
33	Thymic dendritic cells express inducible nitric oxide synthase and generate nitric oxide in response to self- and alloantigens. *Journal of Immunology*, **2000**, 164, 4649-58	5.3	55
32	17beta-estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases. *American Journal of Physiology - Renal Physiology*, **2000**, 279, F626-35	4.3	22
31	Nitric oxide/L-arginine in uremia. *Mineral and Electrolyte Metabolism*, **1999**, 25, 384-90		17
30	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. *Blood*, **1999**, 94, 610-620	2.2	42

29	Uremic Bleeding: Closing the Circle After 30 Years of Controversies?. *Blood*, **1999**, 94, 2569-2574	2.2	158
28	Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions?. *Circulation*, **1999**, 100, 55-60	16.7	181
27	Peripheral donor leukocytes prolong survival of rat renal allografts. *Kidney International*, **1999**, 56, 1101-12	9.9	30
26	IgA nephropathy: a stem cell disease?. *Kidney International*, **1999**, 56, 1964-6	9.9	5
25	Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. *American Journal of Kidney Diseases*, **1999**, 33, 746-53	7.4	40
24	Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. *Journal of the American Society of Nephrology: JASN*, **1999**, 10, 281-93	12.7	113
23	Peripheral donor leukocytes prolong survival of rat renal allografts. *Kidney International*, **1999**, 56, 1101	9.9	13
22	Physiology and pathophysiology of nitric oxide in chronic renal disease. *Proceedings of the Association of American Physicians*, **1999**, 111, 602-10		33
21	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. *Blood*, **1999**, 94, 610-620	2.2	1
20	Are HUS and TTP genetically determined?. *Kidney International*, **1998**, 53, 1085-6	9.9	5
19	Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: implications for dialysis hypotension. *American Journal of Kidney Diseases*, **1998**, 32, 115-24	7.4	67
18	Identification of a novel gene--SSK1--in human endothelial cells exposed to shear stress. *Biochemical and Biophysical Research Communications*, **1998**, 246, 881-7	3.4	6
17	Nitric oxide as a mediator of hemodynamic disturbances in acute renal failure associated with sepsis **1998**, 575-589		
16	Renal and systemic nitric oxide synthesis in rats with renal mass reduction. *Kidney International*, **1997**, 52, 171-81	9.9	112
15	Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction. *Transplantation*, **1997**, 63, 1508-14	1.8	45
14	A Putative Role of NO and Oxidant Injury in the Pathogenesis of Hemolytic Uremic Syndrome **1997**, 418-427		
13	Increased nitric oxide formation in recurrent thrombotic microangiopathies: a possible mediator of microvascular injury. *American Journal of Kidney Diseases*, **1996**, 27, 790-6	7.4	42
12	Systemic and fetal-maternal nitric oxide synthesis in normal pregnancy and pre-eclampsia. *BJOG: an International Journal of Obstetrics and Gynaecology*, **1996**, 103, 879-86	3.7	51

11	alpha 1-Antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. *Lancet, The*, **1995**, 345, 224-5	40	20
10	New insights into circulating cell-endothelium interactions and their significance for glomerular pathophysiology. *American Journal of Kidney Diseases*, **1995**, 26, 541-8	7.4	24
9	Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. *Circulation Research*, **1995**, 76, 536-43	15.7	371
8	Thromboxane A2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts induced by thymic recognition of major histocompatibility allopeptides. *Journal of Experimental Medicine*, **1994**, 180, 1967-72	16.6	34
7	Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. *Kidney International*, **1993**, 44, 445-50	9.9	142
6	Defective glomerular [3H]lysoPAF metabolism in the autologous phase of rabbit nephrotoxic nephritis. *Kidney International*, **1993**, 44, 747-54	9.9	1
5	Urinary excretion of platelet activating factor in patients with immune-mediated glomerulonephritis. *Kidney International*, **1993**, 43, 426-9	9.9	17
4	Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome. *Lancet, The*, **1992**, 339, 835-6	40	24
3	Renal prostacyclin biosynthesis is reduced in children with hemolytic-uremic syndrome in the context of systemic platelet activation. *American Journal of Kidney Diseases*, **1992**, 20, 144-9	7.4	23
2	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. *Kidney International*, **1992**, 42, 981-90	9.9	17
1	Increased urinary excretion of platelet activating factor in mice with lupus nephritis. *Life Sciences*, **1991**, 48, 1429-37	6.8	13